|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPIF |
Gene summary for PPIF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPIF | Gene ID | 10105 |
| Gene name | peptidylprolyl isomerase F | |
| Gene Alias | CYP3 | |
| Cytomap | 10q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | A0A024QZS4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10105 | PPIF | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.29e-08 | 1.85e-01 | 0.0155 |
| 10105 | PPIF | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.04e-08 | 3.70e-01 | -0.1808 |
| 10105 | PPIF | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.39e-12 | 3.54e-01 | -0.0811 |
| 10105 | PPIF | HTA11_78_2000001011 | Human | Colorectum | AD | 3.96e-05 | 2.58e-01 | -0.1088 |
| 10105 | PPIF | HTA11_347_2000001011 | Human | Colorectum | AD | 2.35e-24 | 6.11e-01 | -0.1954 |
| 10105 | PPIF | HTA11_411_2000001011 | Human | Colorectum | SER | 5.18e-07 | 5.53e-01 | -0.2602 |
| 10105 | PPIF | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.21e-02 | 4.05e-01 | -0.2196 |
| 10105 | PPIF | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.31e-07 | 4.18e-01 | -0.1207 |
| 10105 | PPIF | HTA11_83_2000001011 | Human | Colorectum | SER | 3.11e-06 | 3.72e-01 | -0.1526 |
| 10105 | PPIF | HTA11_696_2000001011 | Human | Colorectum | AD | 3.50e-14 | 4.00e-01 | -0.1464 |
| 10105 | PPIF | HTA11_866_2000001011 | Human | Colorectum | AD | 2.30e-06 | 2.12e-01 | -0.1001 |
| 10105 | PPIF | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.19e-17 | 5.35e-01 | -0.059 |
| 10105 | PPIF | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.90e-05 | 5.38e-01 | -0.2061 |
| 10105 | PPIF | HTA11_546_2000001011 | Human | Colorectum | AD | 1.78e-02 | 2.99e-01 | -0.0842 |
| 10105 | PPIF | HTA11_7862_2000001011 | Human | Colorectum | AD | 7.73e-05 | 3.89e-01 | -0.0179 |
| 10105 | PPIF | HTA11_866_3004761011 | Human | Colorectum | AD | 3.21e-08 | 2.93e-01 | 0.096 |
| 10105 | PPIF | HTA11_8622_2000001021 | Human | Colorectum | SER | 6.40e-03 | 2.60e-01 | 0.0528 |
| 10105 | PPIF | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.57e-04 | 2.62e-01 | 0.0131 |
| 10105 | PPIF | HTA11_10623_2000001011 | Human | Colorectum | AD | 1.41e-07 | 3.40e-01 | -0.0177 |
| 10105 | PPIF | HTA11_6801_2000001011 | Human | Colorectum | SER | 3.55e-13 | 8.96e-01 | 0.0171 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004345715 | Thyroid | PTC | regulation of cellular respiration | 28/5968 | 49/18723 | 2.25e-04 | 1.64e-03 | 28 |
| GO:000183625 | Thyroid | PTC | release of cytochrome c from mitochondria | 32/5968 | 59/18723 | 3.06e-04 | 2.14e-03 | 32 |
| GO:00029314 | Thyroid | PTC | response to ischemia | 31/5968 | 58/18723 | 5.31e-04 | 3.41e-03 | 31 |
| GO:00902006 | Thyroid | PTC | positive regulation of release of cytochrome c from mitochondria | 17/5968 | 28/18723 | 1.55e-03 | 8.63e-03 | 17 |
| GO:005159219 | Thyroid | PTC | response to calcium ion | 65/5968 | 149/18723 | 1.67e-03 | 9.16e-03 | 65 |
| GO:003579410 | Thyroid | PTC | positive regulation of mitochondrial membrane permeability | 23/5968 | 43/18723 | 2.66e-03 | 1.35e-02 | 23 |
| GO:009019910 | Thyroid | PTC | regulation of release of cytochrome c from mitochondria | 25/5968 | 48/18723 | 2.86e-03 | 1.42e-02 | 25 |
| GO:0071241110 | Thyroid | PTC | cellular response to inorganic substance | 92/5968 | 226/18723 | 3.01e-03 | 1.49e-02 | 92 |
| GO:0051346112 | Thyroid | PTC | negative regulation of hydrolase activity | 146/5968 | 379/18723 | 3.33e-03 | 1.62e-02 | 146 |
| GO:001082318 | Thyroid | PTC | negative regulation of mitochondrion organization | 25/5968 | 49/18723 | 4.09e-03 | 1.95e-02 | 25 |
| GO:190268615 | Thyroid | PTC | mitochondrial outer membrane permeabilization involved in programmed cell death | 21/5968 | 40/18723 | 5.37e-03 | 2.47e-02 | 21 |
| GO:00510518 | Thyroid | PTC | negative regulation of transport | 176/5968 | 470/18723 | 5.44e-03 | 2.49e-02 | 176 |
| GO:190571010 | Thyroid | PTC | positive regulation of membrane permeability | 24/5968 | 48/18723 | 6.73e-03 | 2.90e-02 | 24 |
| GO:00434629 | Thyroid | PTC | regulation of ATPase activity | 23/5968 | 46/18723 | 7.89e-03 | 3.33e-02 | 23 |
| GO:00702656 | Thyroid | PTC | necrotic cell death | 29/5968 | 62/18723 | 9.96e-03 | 4.07e-02 | 29 |
| GO:000208211 | Thyroid | PTC | regulation of oxidative phosphorylation | 13/5968 | 23/18723 | 1.25e-02 | 4.88e-02 | 13 |
| GO:0071248110 | Thyroid | PTC | cellular response to metal ion | 78/5968 | 197/18723 | 1.29e-02 | 4.98e-02 | 78 |
| GO:000645733 | Thyroid | ATC | protein folding | 140/6293 | 212/18723 | 3.46e-22 | 8.09e-20 | 140 |
| GO:200123335 | Thyroid | ATC | regulation of apoptotic signaling pathway | 206/6293 | 356/18723 | 2.81e-21 | 5.92e-19 | 206 |
| GO:000697934 | Thyroid | ATC | response to oxidative stress | 246/6293 | 446/18723 | 2.98e-21 | 6.09e-19 | 246 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05012 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
| hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
| hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
| hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa05016 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
| hsa05020 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
| hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa05017 | Colorectum | AD | Spinocerebellar ataxia | 60/2092 | 143/8465 | 3.78e-06 | 4.35e-05 | 2.78e-05 | 60 |
| hsa050121 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
| hsa052081 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
| hsa054151 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
| hsa050101 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa050161 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
| hsa050201 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
| hsa050221 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa050171 | Colorectum | AD | Spinocerebellar ataxia | 60/2092 | 143/8465 | 3.78e-06 | 4.35e-05 | 2.78e-05 | 60 |
| hsa050122 | Colorectum | SER | Parkinson disease | 132/1580 | 266/8465 | 2.72e-31 | 9.03e-29 | 6.55e-29 | 132 |
| hsa054152 | Colorectum | SER | Diabetic cardiomyopathy | 103/1580 | 203/8465 | 1.45e-25 | 1.61e-23 | 1.17e-23 | 103 |
| hsa050202 | Colorectum | SER | Prion disease | 119/1580 | 273/8465 | 4.61e-22 | 3.06e-20 | 2.22e-20 | 119 |
| hsa052082 | Colorectum | SER | Chemical carcinogenesis - reactive oxygen species | 103/1580 | 223/8465 | 1.60e-21 | 7.57e-20 | 5.50e-20 | 103 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPIF | SNV | Missense_Mutation | novel | c.620N>A | p.Ser207Asn | p.S207N | P30405 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PPIF | insertion | In_Frame_Ins | novel | c.618_619insCTTGTTCCTTTGACTCTTGACTCATCATTCATGACCGTT | p.Leu206_Ser207insLeuValProLeuThrLeuAspSerSerPheMetThrVal | p.L206_S207insLVPLTLDSSFMTV | P30405 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PPIF | deletion | In_Frame_Del | novel | c.551_553delNNN | p.Ile184_Glu185delinsLys | p.I184_E185delinsK | P30405 | protein_coding | TCGA-E9-A5FK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR | ||
| PPIF | SNV | Missense_Mutation | novel | c.228N>T | p.Glu76Asp | p.E76D | P30405 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PPIF | SNV | Missense_Mutation | novel | c.365N>T | p.Gly122Val | p.G122V | P30405 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.995) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PPIF | SNV | Missense_Mutation | rs145899672 | c.265N>A | p.Gly89Ser | p.G89S | P30405 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PPIF | SNV | Missense_Mutation | rs371203826 | c.211G>A | p.Val71Ile | p.V71I | P30405 | protein_coding | deleterious_low_confidence(0.02) | benign(0.404) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| PPIF | SNV | Missense_Mutation | c.569N>G | p.Lys190Arg | p.K190R | P30405 | protein_coding | tolerated_low_confidence(0.69) | benign(0.006) | TCGA-BS-A0TA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD | |
| PPIF | SNV | Missense_Mutation | rs771871615 | c.364G>A | p.Gly122Arg | p.G122R | P30405 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.654) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PPIF | SNV | Missense_Mutation | novel | c.280A>C | p.Thr94Pro | p.T94P | P30405 | protein_coding | tolerated_low_confidence(0.08) | possibly_damaging(0.864) | TCGA-D1-A0ZP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |